Preoperative window of opportunity study with giraredestrant (GDC-9545) or tamoxifen in premenopausal women with early-stage breast cancer (EBC) ER[+]/HER2[-] and Ki67=10%”. – The EMPRESS study

CLINICAL TRIAL WITH MEDICINES